As of April 19, 2025, Pyxis Oncology (PYXS) has a market cap of $59.330 million USD. According to our data, Pyxis Oncology is ranked No.7952 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 19, 2025 | $59.33 M |
-36.04%
|
Dec 31, 2024 | $92.77 M |
-13.33%
|
Dec 29, 2023 | $0.11 B |
34.33%
|
Dec 30, 2022 | $79.68 M |
-87.78%
|
Dec 31, 2021 | $0.65 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() MacroGenics
MGNX
|
$79.49 M |
-0.000 M
|
![]() USA
|
![]() Zymeworks
ZYME
|
$0.80 B |
-0.000 M
|
![]() Canada
|
![]() Iovance Biotherapeutics
IOVA
|
$1.00 B |
-0.000 M
|
![]() USA
|
![]() Adaptimmune Therapeutics
ADAP
|
$61.27 M |
0.051 M
|
![]() UK
|
![]() Fate Therapeutics
FATE
|
$0.13 B |
0.000 M
|
![]() USA
|
![]() Allogene Therapeutics
ALLO
|
$0.32 B |
-0.000 M
|
![]() USA
|
![]() bluebird bio
BLUE
|
$40.53 M |
0.000 M
|
![]() USA
|
![]() Beam Therapeutics
BEAM
|
$1.70 B |
0.000 M
|
![]() USA
|
![]() CRISPR Therapeutics
CRSP
|
$3.26 B |
0.000 M
|
![]() Switzerland
|
![]() Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
![]() USA
|
![]() Intellia Therapeutics
NTLA
|
$0.75 B |
-0.000 M
|
![]() USA
|
![]() Sangamo Therapeutics
SGMO
|
$0.16 B |
-0.989 M
|
![]() USA
|
![]() Arcus Biosciences
RCUS
|
$0.83 B |
-0.000 M
|
![]() USA
|
![]() Gritstone bio
GRTS
|
$3.80 M |
2.350 M
|
![]() USA
|
Market Cap | = | PYXS Stock Price | * | PYXS Shares Outstanding |
= | $0.96 | * | 61.59 M | |
= | $59.33 M |